• OrthoPediatrics signed an exclusive U.S. distribution agreement with OSSIO for bio-integrative, metal-free orthopedic fixation implants for children’s hospitals.
• Deal adds OSSIOfiber implants used in pediatric fracture and deformity procedures, targeting fewer secondary surgeries to remove metal hardware.
• Implants are designed to match initial metal-like fixation strength, then integrate into bone within 18-24 months, leaving no hardware behind.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrthoPediatrics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606240705PRIMZONEFULLFEED9751596) on June 24, 2026, and is solely responsible for the information contained therein.